NoAb BioDiscoveries

Technologies to accelerate the drug discovery process; development of therapeutic drug candidates

The company was founded in 1996 as NoAb Diagnostics. In 2001 the drug discovery business became an addition calling for a name-change to NoAb BioDiscoveries.

Dan Lichtman (CEO)
David K. H. Lee (CSO)
Cathy Trewin (CFO)

2820 Argentia Road, Unit 8
Mississauga, Ontario, L5N 8G4
Canada
Phone: +1-905-814-5238
Fax: +1-905-814-5241

BioDScreen™ is a group of three suites of in-vitro ADME studies applicable for screening compounds.